Biomea Fusion, Inc.
BMEAHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeBiomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. The company carries a $146.8M market cap, placing it firmly in the micro-cap category. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Market Cap
$146.8M
Beta
-0.24
P/E (TTM)
—
P/E (Fwd)
-2.16
EPS (TTM)
$-0.18
EPS (Fwd)
$-0.94
ROE
-164.1%
ROA
-63.5%
Cash
$34.8M
Total Debt
$877,000
Free CF
-$27.8M
52W Change
12.2%
Annual Financials
Cash vs Debt
Where BMEA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BMEA finished 38.57% above its 150-day moving average ($1.40) and 41.61% above its 200-day moving average ($1.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMEA overbought or oversold?
At the September 3, 2026 close, BMEA's RSI(14) was 85.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $34.8M in cash comfortably exceeding the $877K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$27.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -164.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Biomea Fusion, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, BMEA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Biomea Fusion, Inc. and its sector.